Introduction
============

Bevacizumab, the classical anti-angiogenesis drug, had been expected to both prune the immature vessels and normalize tumor vessels by decreasing interstitial fluid pressure and increasing the delivery of drugs and oxygen[@B1]. It had been approved by the US Food and Drug Administration (FDA) to be used in various cancers such as metastatic colorectal cancer (mCRC)[@B2]-[@B7], advanced non-small cell lung cancer (NSCLC)[@B8], [@B9], advanced renal cell carcinoma[@B10], [@B11], metastatic breast cancer[@B12], [@B13] and so on.

In metastatic colorectal cancer (mCRC), bevacizumab was widely used in the first- [@B2], [@B6], second- [@B7], later-line treatment[@B14] and even progression beyond its failure[@B15]. However, the administration of bevacizumab had always been challenged. Though both of PFS and OS were improved significantly in AVF2017, ARTIST, and E3200 trials[@B2], [@B3], [@B7], the original short OS of IFL regimen in the former two trials weakened their significances. Moreover, only PFS rather than OS was significantly improved in the NO16966 trial[@B16], which was also the main reason of FDA withdrawing the license of bevacizumab when combined with pacelitaxel in the first line setting of metastatic breast cancer[@B17]-[@B20].

Bevacizumab is available in the treatment of first-, second-, later-line and even beyond its initial disease progression for mCRC, and the efficacy might increasing with treatment course. However, not all patients had the opportunity to receive bevacizumab treatment. In the developing countries and the countries with incomplete health insurance, mCRC patients could only receive the expensive drug in just one-line of the whole treatment. Then, the current question is that which line therapy is more beneficial with the combination of bevacizumab? Current researches of it had not been found yet. A previous study of us had analyzed a small sample of Chinese mCRC, the result showed that the OS of bevacizumab combined group is much more longer than chemotherapy alone group, while it had no statistically difference between the first- and second-line of bevaciumab combined treatment[@B21]. The current study expanded the sample size and prolonged the follow-up time, and the aim of it is not only to confirm our previous result but also offer some valuable data to the mCRC patients with limited opportunity to receive bevacizumab treatment.

Materials and methods
=====================

Study population
----------------

Patients who met the following criterions were selected as study group: 1) Diagnosed as mCRC based on pathological specimens of the primary tumor, at the same time with clinical and/or pathological evidences of distant metastasis lesion, at the Sun Yat-sen University Cancer Center from 2007 to 2013 and finished the entire course of first- and second-line chemotherapy in this center 2) Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; 3) Bevacizumab was added to the palliative regimens including oxaliplatin-based, irinotecan-based regimens and so on; 4) More than 4 cycles of bevacizumab was required, since 4 cycles was considered the minimum course for the patients got benefit from bevacizummab in our previous study[@B22]. Meanwhile, the consecutive mCRC patients in the control group met the same criterions with the study group except for bevacizumab administration. The exclusion criterions of both groups included 1) No pathological diagnosis; 2) Unclear medical histories; 3) Bevacizumab beyond its initial disease progression[@B15].

Evaluation of efficacy
----------------------

The short-term effect was evaluated by the independent group based-on criterion of RESIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors): overall response rate (ORR), disease control rate (DCR); the long-term efficacy was evaluated by comparing overall survival (OS) and progression free survival (PFS).

Assessment
----------

Patients\' OS, PFS, ORR and DCR were the primary statistical endpoints of the study. OS was calculated from diagnosis to death or the date of last follow-up (December 25^th^, 2015), and PFS was deemed to be the period from the initial treatment of bevacizumab to the progression date by imaging examination according to the RECIST 1.1 criteria.

Statistical analyses
--------------------

Survival curves were estimated using the Kaplan-Meier method. All the statistical analysis was conducted by SPSS 18.0 software package and the P value less than 0.05 was considered with statistically significant.

Follow up
---------

The last follow-up was conducted on December 25^th^, 2015 through telephone interview or medical records review. All the patients in the study and the control group were followed up closely by then.

Human Rights
------------

All the patients\' information in our study has got IRB Approval of our hospital.

Results
=======

Patient characteristics and therapeutic regimens
------------------------------------------------

There were 82 patients entered the study group, all of them received bevacizumab (5 mg/kg, every two weeks) combined with chemotherapy in first- or second-line treatment. In the first-line of study group, there were 29 and 31 patients treated with oxaliplatin-based (FOLFOX and XELOX) and irinotecan-based (FOLFIRI, IFL, CPT-11 plus xeloda) chemotherapy, respectively; the median cycles of bevacizumab were 9.62 (ranged from 4\~25). In the second-line treamtment, 12 and 10 patients were treated with oxaliplatin-based and irinotecan-based chemotherapy, respectively; the median cycles of bevacizumab were 6.86 (ranged from 4\~15). While in the first- and second-line of control group, 446 patients were treated with chemotherapy alone. Patients were treated with oxaliplatin-based, irinotecan-based and other chemotherapy as well, which is shown in Table [3](#T3){ref-type="table"}. All the patients\' characteristics and potential prognostic factors including sex, age, tumor location, pathological type and receiving third-line treatment or not were balanceable between the study group and the control group (Table [1](#T1){ref-type="table"}). In the study group, 98.8% (81/82) and 42.7% (35/82) patients exhibited progressed and died, and 100% (446/446) patients and 64.6% (288/446) patients exhibited progressed and died in the control group (Table [2](#T2){ref-type="table"}).

Efficacy of bevacizumab in different lines
------------------------------------------

In the entire group, the median OS of the study and the control group were 44.8 (95% CI: 37.1\~52.4) months, 36.1 (95% CI: 32.8\~39.5) months (P=0.004), respectively (Fig.[1](#F1){ref-type="fig"}).

The median OS of study group and control group in the first-line were 49.9(95% CI: 40.1\~59.8) months and 36.1 (95% CI: 32.7\~39.4) months (P=0.002); in the second-line were 34.8 (95% CI: 26.3\~43.3) months and 24.6 (95% CI: 22.2\~27.0) months (P=0.022), respectively (Fig.[2](#F2){ref-type="fig"}, Fig.[3](#F3){ref-type="fig"}).

The median PFS of the study group and control group in the first-line were 10.1(95% CI: 8.7\~11.5) months and 6.2 (95% CI: 5.5\~6.8) months (P\<0.001); in the second-line were 6.3 (95% CI: 4.7\~7.8) months months and 3.1 (95% CI: 2.5\~3.6) months (P\<0.001), respectively (Fig.[4](#F4){ref-type="fig"}, Fig.[5](#F5){ref-type="fig"}).

In the study group, the meidan OS of the first- and second-line treatment were 49.9(95% CI: 40.1\~59.8) and 34.8 (95% CI: 26.3\~43.3) months (P=0.189), respectively (Fig.[6](#F6){ref-type="fig"}). The ORR were 30% (18/60), 22.7% (5/22); DCR were 63.3% (38/60), 59.1% (13/22) (P=0.359), respectively (Table [2](#T2){ref-type="table"}).

Discussion
==========

The similar effect of bevacizumab in Caucasian mCRC patients and Chinese mCRC patients was indicated in clinical trials of AVF2017[@B2] and ARTIST[@B3]. However, In Chinese mCRC patients, the experiences of bevacizumab need accumulating. The early one-armed study of bevaczimab in Chinese mCRC patients found higher mortality and progressive rate (56.3% and 40.6%, respectively), which may relate to small patient sample. Later, both a recent study[@B23] and our data[@B22], [@B24], [@B25] showed that OS was significantly prolonged after the administration of bevacizumab in mCRC, even in the later line[@B14]. In addition, our studies also found that only patients received more than 4 cycles of bevacizumab can get survival benefit[@B22] and bevacizumab benefit only refine to patients with initial LDH increase before treatment.

To our best knowledge, the current study was the first study to compare the effect of bevacizumab among different lines treatment when combined with chemotherapy in mCRC. It was shown that not only ORR and DCR but also OS and PFS were promising after the addition of bevacizumab in each line treatment. In the entire group, the OS was prolonged indeed with the addition of bevacizumab when compared with patients without bevacizumab. Furthermore, both of OS and PFS were significant improved in bevacizumab group when compared with corresponding line chemotherapy alone groups. However, the OS were statistically insignificant among different line subgroups of bevacizumab group. All the patients in our study only received one line bevacizumab treatment since the patients received bevacizumab beyond its initial progression were excluded. Meanwhile, the current data, accordant with other studies, demostrated that the combination of bevacizumab and standard chemotherapy really brought survival benefit to mCRC patients no matter it was added in the first- or the second-line treatment. The exact cause is unknown, but a similar finding was seen in non-small cell lung cancer(NSCLC) patients who were EGFR sensitive mutations and treated with tyrosine kinase inhibitors(TKIs)[@B26]. Both clinical trials of IPASS and NEJSG002[@B27], [@B28] were to investigate the sequence of gefitinib, the first generation of TKIs and chemotherapy in the first line and second line in patients with EGFR sensitive mutation. The OS were identical no matter the first- and second- line strategy was chemotherapy behind TKIs or the opposite, despite that the PFS of TKIs group was longer than chemotherapy in the first line. Therefore, the principle of TKIs administration was that it could be used in no matter which line. The reason of this phenomenon was unknown either in NSCLC patients as well.

Besides, the limits of this study should be taken into account before drawing a conclusion. Firstly, the retrospective data and small patients sample may cause bias. In addition, although this strategy were proven to be effective and be part of clinical practice already, the patients treated with bevacizumab beyond its initial progression were not covered in this study. The aim of excluding those patients was to guarantee the drug was received once in the patients of the study group during the whole course of treatment. As a consequence, it was possible to be compared with the patients in chemotherapy alone group. Moreover, only patients received more than four cycles of bevacizumab were recruited, since our previous study found the survival benefit refine to those group of mCRC patients.

In conclusion, once the patients received bevacizumab during the whole course of treatment, it really brought survival benefit to mCRC patients in no matter which line therapy. Nevertheless, the prospective and/or larger patients sample studies are urgently needed.
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###### 

Patient baseline characteristics in the study and the control group.

  ----------------------------------------------------------------------------------------
  Patient\                        Control group   Study group   P\*                     
  characteristics                                                                       
  ------------------------------- --------------- ------------- ------- ------- ------- --
  Number                          446             82                                    

  Gender                                                                                

  Male                            297 (66.6%)     53 (64.6%)    0.730   0.325   0.213   

  Female                          149 (33.4%)     29 (35.4%)                            

  Age (years)                                                                           

  Median (range)                  54 (16\~84)     53 (20\~78)   0.181   0.154   0.820   

  ≤65                             352 (78.9%)     70 (85.4%)                            

  \>65                            94 (21.1%)      12 (14.6%)                            

  Primary tumor                                                                         

  Colon                           295 (66.1%)     55 (67.1%)    0.870   0.583   0.222   

  Rectum                          151 (33.9%)     27 (32.9%)                            

  Pathological type                                                                     

  Adenocarcinoma                  413 (92.6%)     77 (93.9%)    0.675   0.907   0.628   

  Others                          33 (7.4%)       5 (6.1%)                              

  Accepted three-line treatment                                 0.676   0.478   0.791   

  Yes                             106 (23.8%)     21 (25.6%)                            

  No                              340 (76.2%)     61 (74.4%)                            

                                                                                        
  ----------------------------------------------------------------------------------------

**Study group:**the group of patients receiving bevacizumab.

**Control group:** the group of patients not receiving bevacizumab.

P\*1**:** the balance test P value of total patients.

P\*2**:**the balance test P value of the first-line regimen.

P\*3**:** the balance test P value of the second-line regimen.

###### 

The efficacy of bevacizumab in the study group.

  ------------------------------------------------------------------------
  Patient\          Bevacizumab group          
  characteristics                              
  ----------------- -------------------------- ---------------------------
  Number            60                         22

  ORR (%)           30% (18/60)                22.7% (5/22)

  DCR (%)           63.3% (38/60)              59.1% (13/22)

  PFS (months)      10.1(95% CI: 8.7\~11.5)    6.3 (95% CI: 4.7\~7.8)

  OS (months)       49.9(95% CI: 40.1\~59.8)   34.8 (95% CI: 26.3\~43.3)
  ------------------------------------------------------------------------

###### 

The first and second-line chemotherapy regimen of control and study group

  Patient characteristics   First-line   Second-line         
  ------------------------- ------------ ------------- ----- ----
  Number                    446          60            163   22
  Oxaliplatin based         357          29            41    12
  Irinotecan based          75           31            113   10
  Other chemotherapy        14           0             9     0

**Study group:**the group of patients receiving bevacizumab; oxaliplatin-based: FOLFOX, XELOX; irinotecan-based: FOLFIRI, IFL, CPT-11+xeloda.

**Control group:** the group of patients not receiving bevacizumab; oxaliplatin-based: FOLFOX, XELOX, oxaliplatin+S-1; irinotecan-based: FOLFIRI, CPT-11+S-1
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